^
Association details:
Biomarker:AKT1 mutation
Cancer:Solid Tumor
Drug:vevorisertib (ARQ 751) (pan-AKT inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors

Published date:
03/27/2023
Excerpt:
Vevorisertib alone or with paclitaxel or fulvestrant had a manageable safety profile, and vevorisertib alone or with paclitaxel had minimal to modest antitumor activity in this patient population with PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Secondary therapy:
fulvestrant; paclitaxel
DOI:
10.1002/cncr.34733
Trial ID: